Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Shares Outstanding (2016 - 2025)

Collegium Pharmaceutical (COLL) has 7 years of Shares Outstanding data on record, last reported at -$2.5 million in Q2 2022.

  • For Q2 2022, Shares Outstanding fell 106.92% year-over-year to -$2.5 million; the TTM value through Jun 2022 reached -$2.5 million, down 106.92%, while the annual FY2021 figure was $35.8 million, 3.45% up from the prior year.
  • Shares Outstanding reached -$2.5 million in Q2 2022 per COLL's latest filing, roughly flat from -$2.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $35.8 million in Q4 2021 and bottomed at -$2.5 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $30.1 million, with a median of $33.6 million recorded in 2019.
  • Peak YoY movement for Shares Outstanding: increased 12.22% in 2018, then plummeted 106.92% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $33.3 million in 2018, then rose by 1.24% to $33.7 million in 2019, then grew by 2.77% to $34.6 million in 2020, then grew by 3.45% to $35.8 million in 2021, then tumbled by 106.86% to -$2.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were -$2.5 million in Q2 2022, $36.4 million in Q1 2022, and $35.8 million in Q4 2021.